	Data of Davidson	A	Deticals (additional details available consent)
Drug Considered (Generic)	Date of Review 4/4/2014	Approved N	
Aripiprazole long acting in Asenapine	4/4/2014 3/5/2010, 5/6/2011, 4/10/2015	N Y	Lack of safety and efficacy data in children and adolescents.  Restricted to children/adolescents 10-17 years of age.
Atenolol	9/4/2009	N N	Removed due to lack of safety data and experience with use in children and adolescents.
Duloxetine	2/4/05 & 5/5/06	N	Lack of data re safety and efficacy in children for psychiatric indications.
Duloxetine	5/7/2010 & 10/5/2012	N	Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.
Duloxetine	6/5/2015	Y	Approved as per FDA approval restricted to: GAD, Ages 7-17
Felbamate	10/8/2004	N	No indication for use as a psychotropic medication in children.
Fluphenazine decanoate Guanfacine XR	4/4/2014 10/9/2009	Y N	Only for children >=13yrs old.
Guantacine XR Guanfacine XR	2/5/2010	Y Y	Pending further data once drug is actually available.  Safety and efficacy data now available. Reviewed and approved.
Haloperidol decanoate	4/4/2014	<u>'</u>	Only for children >=13yrs old.
Herbals/Nutritional Suppl	4/1/2005	N	Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.
lloperidone	3/5/2010, 4/10/2015	N	Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern
Lamotrigine XR	8/6/2010	Y	But with a warning for use in children <13yrs old dure to lack of evidence for safety and efficacy in this age group.
Lurasidone	5/6/2011, 10/5/2012, 4/10/2015	N	Pending release of data regarding use in chidren or adolescents. Must be given with 300cal meal. May increase prolactin levels.
Melatonin	1/6/06, 5/5/06, 1/6/08 4/5/2013	N Y	Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.
Methylphenidate ER liquid Metoprolol	9/4/2009	N N	Similar to other methylphenidate products already approved.  Removed due to lack of safety data and experience with use in children and adolescents.
Molindone	12/4/2009	Y	Associated with weight loss vs. gain. To remain on the approved drug list.
Molindone	11/5/2010	N	No longer available on the market.
Nadolol	1/7/2011	N	Removed due to lack indication for use in children and adolescents.
Nefazodone	8/5/2004, 06/05/2015	N	ADR profile: Liver toxicity.
Olanzapine long acting inj	4/4/2014	N	Lack of safety and efficacy data in children and adolescents.
Olanzapine	2/5/2010	Y	On approved list but restricted to DCF MD review. Based on FDA required change in prescribing information relating to weight gain.
Oxcarbazepine Oxcarbazepine	12/1/2006 5/1/2009, 5/7/2010	N N	Lack of data re efficacy in children for psychiatric indications.  Lack of safety-efficacy data in children. No new data available since last review.
Oxcarbazepine Oxcarbazepine	12/6/2013, 5/1/2015	N N	Lack of safety-efficacy data in children. No new data available since last review.  Lack of safety-efficacy data in children. No new data available since last review.
Paliperidone	9/4/2009 & 5/6/2011	Y	Lack of safety-efficacy data in children. No new data available since last review.
Paliperidone long acting inj	4/4/2014	Ň	Lack of safety and efficacy data in children and adolescents.
Paroxetine	3/5/2004, 06/05/2015	N	Higher risk of suicide per FDA advisory. Reports of liver failure.
Pemoline	8/5/2004	N	Withdrawn from market
Pimozide	9/5/2008	N	ADR profile: EKG changes - QT prolongation.
Prazosin	6/5/2009 & 2/1/13	Y Y	Approved with age based max dosing
Risperidone long acting inj Ramelteon	4/4/2014 9/4/2009	N N	Only for children >=13yrs old. Lack of safety-efficacy data in children. Data may be available Feb 2010.
Thioridazine	8/5/2004	N	ADR profile: EKG changes - QT prolongation.
Tiagabine	10/8/2004, 5/1/2015	N	Lack of data re safety and efficacy in children for psychiatric indications.
Topiramate	12/1/2006, 5/1/2015	N	Lack of data re efficacy in children for psychiatric indications.
Trazodone XR	8/6/2010	N	No advantage over trazodone IR when used for insommnia.
Venlafaxine	3/5/2004 & 5/6/2011	Y	Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.
Verapamil Vilazodone	1/7/2011 10/5/2012	N N	Removed due to lack indication for use in children and adolescents.
Zaleplon	5/1/2015	N N	Pending results of clinical trials underway iinvolving children/adolescents.
Zolpidem	5/1/2015	N	Removed due to lack of data regarding use in children/adolescents.  Removed: study of 201 children showed no efficacy and significant adverse drug reactions.
			To the country of 20 and an extension of the country of the countr
Drug Considered (Brand)	Date of Review 4/4/2014	Approved N	
Abilify Maintena Ambien	5/1/2015		Lack of safety and efficacy data in children and adolescents.  Removed: study of 201 children showed no efficacy and significant adverse drug reactions.
LCorgard		N N	Removed due to lack indication for use in children and adolescents
Corgard Cylert	1/7/2011 8/5/2004	N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market
Cylert Cymbalta	1/7/2011 8/5/2004 2/4/05 & 5/5/06	N N N	Removed due to lack indication for use in children and adolescents. Withdrawn from market Lack of data re safety and efficacy in children for psychiatric indications.
Cylert Cymbalta Cymbalta	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012	N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015	N N N N Y	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted for GAD, Ages 7-17
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015 3/5/2004 & 5/6/2011	N N N N Y	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015 3/5/2004 & 5/6/2011 3/5/2010, 4/10/2015	N N N N Y Y	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory, New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/6/2012 6/5/2015 3/5/2004 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004 4/4/2014	N N N N Y	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril	1/7/2011 8/5/2004 24/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015 3/5/2004 & 5/6/2011 3/5/2004 (4/10/2015 10/8/2004 4/4/2014 10/8/2004, 5/1/2015	N N N N Y Y N N N	Removed due to lack indication for use in children and adolescents.  Unifordam from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy in children for spechatric indications.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabhril Herbals/Nutritional Suppl	17/72011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015 3/5/2004 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004 4/4/2014 10/8/2004, 5/1/2015	N N N N Y Y N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sonsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of sucide per FDA achieved, New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication inclieren.  Lack of safety and efficacy data in children and ora diolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl	1/7/2011 8/5/2004 2/4/05 & 5/5/06 57/2010 & 10/5/2012 6/5/2015 3/5/2004 & 5/6/2011 3/5/2004 & 5/6/2011 3/5/2004 4/10/2015 4/1/2005 4/1/2005 4/1/2005 4/1/2005 4/1/2005 4/1/2005	N N N N Y Y Y N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwn from market  Lack of data re safety and efficacy in children for psychiatric indications. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. Approved as per FDA approval restricted to: GAD, Ages 7-17 Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.
Cyleri Cymbalta Cymbalta Cymbalta Cymbalta Effekor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2016 & 1/5/5/06 5/7/2016 & 1/5/5/015 6/5/2015 3/5/2004 & 5/6/2011 3/5/2004 & 5/6/2011 10/8/2004 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 3/4/2009 & 5/6/2011	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sonsorred study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and odolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approved for use in children.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Feibatol Haidol Decanoate Gabitril Herbalk-Nutritional Suppl Intuniv Invega	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2010 & 10/5/2012 6/5/2015 3/5/2010 & 5/6/2015 3/5/2010 & 4/10/2015 10/6/2009 & 4/4/2014 10/6/2004 & 4/4/2014 10/6/2004 & 5/1/2015 4/1/2005 10/9/2009 & 5/6/2011 4/4/2014	N N N N Y Y Y N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. OTC interval and orthostasis are a concern.  Not indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for spychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decancate Gabitri Intuniv Invega Invega Sustena Lamictal XR	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2016 & 1/5/5/06 5/7/2016 & 1/5/5/015 6/5/2015 3/5/2004 & 5/6/2011 3/5/2004 & 5/6/2011 10/8/2004 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 3/4/2009 & 5/6/2011	N N N N Y Y N N N N Y Y Y Y N N N N N Y	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sonsorred study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concen. No indication for use as a psychotropic medication in children.  Lack of data re safety and efficacy data in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.  Lack of safety-filicacy data in children. Now has FDA approved for use in children.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decancate Gabitri Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2016 & 1/5/5/06 5/7/2016 & 1/5/5/015 6/5/2015 3/5/2046 & 8/6/2011 3/5/2010, 4/10/2015 10/8/2004, 5/1/2015 4/4/2014 10/8/2004, 5/1/2015 4/4/2001 4/4/2014 4/4/2014 6/6/2014 6/6/2011 6/6/2011, 10/5/2012, 4/10/2015	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sonsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  But with a waming for use in children. Now has FDA approved for use in children.  Lack of safety and efficacy data in children and adolescents.  But with a waming for use in children en 3dys old une to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cat meat. May increase prolactin levels.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haidol Decanoate Gabitri Herbals/Nutritional Suppl Inturuiv Invega Lamictal XR Latuda Lopressor Melatonin	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 1/05/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2004 4/6/2014 8/6/2011 4/6/2015 5/6/2011, 1/05/2012, 4/10/2015 9/4/2009 1/6/06, 5/5/06, 1/6/06	N N N N Y Y Y Y Y N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children 415yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC: on a TPAD regulated medication/spossible inconsistency in formulations of the same product.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Fanapt Felbatol Haldol Decanoate Gabitri Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Mellaril	1/7/2011 8/5/2004 2/4/05 & 5/5/06 5/7/2016 & 10/5/2012 6/5/2015 3/5/2046 & 5/5/06 5/7/2016 & 10/5/2012 6/5/2015 3/5/2046 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004, 5/1/2015 4/4/2014 10/8/2004, 5/1/2015 4/4/2014 8/4/2014 6/4/2014 6/4/2014 6/4/2014 6/4/2014 6/4/2014 6/4/2019 1/5/06, 5/5/06, 1/6/06	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sonsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  But with a warming for use in children and adolescents.  But with a warming for use in children and solescents.  But with a warming for use in children and solescents.  Nut under pervising for use in children and solescents.  Not under pervising for use in children and solescents.  Not under pervise or PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.  Not under pervise or PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haidol Decanoate Gabitri Intruiv Invega Intruiv Invega Sustena Lamictal XR Latuda Lopressor Melatorin Mellarii Minipres	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 5/7/2010 & 1/5/2015 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2004 8/6/2011 4/6/2014 8/6/2011 1/6/05, 5/6/05, 1/6/06 8/6/5/2004 6/5/2004	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwam from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety-efficacy data now arriadable. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children 415yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC not not FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Fanapt Felbatol Haldol Decancate Gabitri Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Mellari Minipres Moban	1/7/2011 8/5/2004 2/4/05 & 5/5/06 2/4/05 & 5/5/06 5/7/2010 & 1/6/5/01 6/5/2015 3/5/204 & 5/6/2015 3/5/204 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2004 & 5/6/2011 4/4/2014 8/5/2015 9/4/2009 1/6/05, 5/5/06, 1/6/08 8/5/2004 6/5/2009 & 2/1/13 12/4/2009	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of data re safety and efficacy in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  But with a warning for use in children and adolescents. Must be given with 300cat meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.  Approviec KGR changes - Of Torlonogation.  Approviec KGR changes - Of Torlonogation.  Approved with age based max dosing
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haidol Decanoate Gabitri Intruiv Invega Intruiv Invega Sustena Lamictal XR Latuda Lopressor Melatorin Mellarii Minipres Moban Moban	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 5/7/2010 & 1/5/2015 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2004 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2004 8/6/2011 4/6/2014 8/6/2011 1/6/05, 5/6/05, 1/6/06 8/6/5/2004 6/5/2004	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwam from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children 415yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC: on tan FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Approved with segible tos the market.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabtril Invega Invega Sustena Lamictal XR Lamictal XR Latuda Lopressor Melatonin Mellaril Minipres Moban Obeptro Oleptro Cymbalta Cymbalta Decanoate Cymbalta Cymb	1/7/2011 8/5/2004 2/4/05 & 5/5/001 2/4/05 & 5/5/001 2/4/05 & 5/5/001 5/7/2010 & 1/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2009 & 5/6/2011 4/6/2009 & 5/6/2011 4/6/2014 5/6/2011, 10/5/2012, 4/10/2015 9/4/2009 1/6/06, 5/5/06, 1/6/08 8/5/2004 6/5/2009 & 2/1/13 12/4/2009 11/5/2010 8/6/2010 8/6/2010 8/6/2010	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfridawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  Lack of safety-efficacy data in children and solescents. Must be given with 300cal meal. May increase prolactin levels.  Pending release of data regarding use in children and adolescents.  Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.  Approved with age based max dosing  Associated with weight loss ex. e.g. in. To remain on the approved drug list.  No longer available on the market.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Mellaril Minipres Moban Moban Moban Oleptro Orap Paxil	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/00 6/5/2015 6/5/2015 3/5/2014 & 5/6/2015 3/5/2014 & 5/6/2015 3/5/2014 & 5/6/2015 10/9/2004 & 5/1/2015 4/4/2014 4/4/2014 4/4/2014 4/4/2014 4/4/2014 6/5/2014 6/5/2015 6/6/2011 6/6/2015 6/6/2011 6/6/2016 6/5/2004 6/5/2009 11/5/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2010 8/6/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/5/2008 8/5/2004 6/6/6/5/2016	N N N N Y Y N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern.  Not indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  But with a warming for use in children. Now has PDA approved.  Lack of safety and efficacy data in children and adolescents.  But with a warming for use in children - 13rys old une to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC: not an FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapi Felbatol Hadsol Decanoate Gabitril Hadsol Decanoate Gabitril Invega Invega Sustena Lamictal XR Latuda Lopressor Melatorin Mellaril Minipres Moban Oleptro Orap Paxil	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/001 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2009 & 5/6/2011 4/4/2014 8/6/2011 4/6/2014 8/6/2011 10/5/2009 & 2/1/13 12/4/2009 1/5/05, 6/5/06, 1/6/06 8/5/2004 6/5/2009 & 2/1/13 12/4/2009 11/5/2010 9/5/2004 0/5/2009 3/5/2004 0/5/2009 3/5/2004 0/5/2009 3/5/2004 0/5/2009 3/5/2004 0/5/2009	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfidrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety-efficacy data in owards of the safety of the safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in owards and approved.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children and adolescents.  But with a warning for use in children and adolescents.  Not under perview of PMAC as the safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase protactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC and the TDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Approved with gae based max dosing  Associated with weight loss vs. gain. To remain on the approved drug list.  No advantage over trazodone IR when used for insommnia.  ADR profile: EKG changes - TD prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.  Only for children -=13yrs old.
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Mellari Minipres Moban Moban Moban Oteptro Orap Paxil Prolixin decanoate Quilliivant	1/7/2011 8/5/2004 2/4/05 & 5/5/06 2/4/05 & 5/5/06 2/4/05 & 5/5/06 5/7/2010 & 1/05/2012 6/5/2015 3/5/2014 & 5/6/2013 3/5/2014, 4/10/2015 10/8/2004, 5/1/2015 4/4/2014 4/4/2014 4/4/2014 4/4/2014 5/5/2008 & 5/6/2011 4/4/2014 6/5/2008 & 2/1/13 11/5/2010 6/5/2008 & 2/1/13 11/5/2010 6/5/2008 & 2/1/13 11/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2008 & 3/5/2010 6/5/2010	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfidrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Also dolescents.  But with a warning for use in children. Also dolescents.  But with a warning for use in children. Also dolescents.  But with a warning for use in children and solescents.  Not under perview of PMAC and the provided of the pr
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Falbatol Haldol Decanoate Gabirti Inturio Invega Invega Sustena Lamictal XR Latuda Lopressor Melatoni Melatoni Melatoni Mohan Oleptro Orap Paxil Prolixin decanoate Quillivant Risperdal Risp	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2009 & 5/6/2011 4/6/2014 8/6/2010 1/6/05, 5/5/05, 1/6/05 8/5/204 6/5/2009 & 2/1/13 11/5/2010 8/6/2010 9/5/2004 6/5/2009 & 2/1/13 11/5/2010 8/6/2010 9/5/2004 3/5/2004, 06/05/2015 4/4/2014 4/5/2013	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety affects of the safety in children for spychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Allowed and approved.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children 413yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC not an FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Approved with gae based max dosing  Associated with weight loss vs. gain. To remain on the approved drug list.  No advantage over trazodone IR when used for insommnia.  ADR profile: EKG changes - OT prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.  Only for
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatorin Mellaril Minipres Moban Oleptro Orap Paxil Prolixin decanoate Quillivant Risperdal Consta Risperdal Consta Risperdal Consta Risperdal Consta Risperdal Consta Rozerem	1/7/2011 8/5/2004 2/4/05 & 5/5/06 2/4/05 & 5/5/06 2/4/05 & 5/5/06 2/4/05 & 5/5/06 2/4/05 & 5/5/06 2/5/2015 & 1/5/2012 6/5/2015 3/5/2014 & 5/6/2015 10/8/2004 & 4/4/2015 10/8/2004 & 5/1/2015 4/1/2005 10/8/2009 & 5/5/2010 9/4/2009 & 5/6/2011 4/4/2014 8/6/2011 10/5/2009 & 5/6/2011 4/4/2014 6/5/2008 & 2/1/13 11/5/2016 & 8/6/2010 9/5/2008 & 2/1/13 11/5/2016 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2008 & 3/5/2010 9/5/2011 4/4/2011 4/4/2014 4/5/2013	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratem from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data no wariable. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Also adolescents.  But with a warming for use in children and adolescents.  Not under pervise of data reparting use in children or adolescents. Must be given with 300-cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under pervise of PMAC. And are PDA regulated medication/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - OT prolongation.  How profile: EKG changes - OT prolongation.  ARR profile: EKG changes - OT prolongation.  Higher risk of suicide per FDA acknowled medication/possible inconsistency in formulations of the same product.  No dynage over trazodone it when used for insommnia.  ARR profile: EKG changes - OT prolongation.  Higher risk of suicide per FDA advisor
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitri Inturiv Invega Inturiv I	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2005 10/9/2009, 3/5/2010 9/4/2009 & 5/6/2011 4/6/2014 8/6/2010 1/6/05, 5/5/05, 1/6/05 8/5/204 6/5/2009 & 2/1/13 11/5/2010 8/6/2010 9/5/2004 6/5/2009 & 2/1/13 11/5/2010 8/6/2010 9/5/2004 3/5/2004, 06/05/2015 4/4/2014 4/5/2013	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfidrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and soft in children.  Lack of safety-efficacy data in oward and approved.  Lack of safety-efficacy data in oward and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children 415yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMACs not an FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Approved with segables on the market.  No advantage over trazodone IR when used for insommnia.  ADR profile: EKG changes - To prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.  Only for children —154yrs old.  Similar to other methylphenidate products already approved.  Only for children —154yrs old.  Lack of safety-efficacy data in children. Data m
Cylent Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatorin Mellaril Minipres Moban Oleptro Orap Paxil Prolixin decanoate Quillivant Risperdal Consta Risperdal Consta Risperdal Consta Risperdal Consta Risperdal Consta Rozerem	1/7/2011 8/5/2004 2/4/05 & 5/5/001 2/4/05 & 5/5/001 5/7/2010 & 1/5/2012 6/5/2015 3/5/2014 & 5/6/2015 3/5/2014 & 5/6/2015 3/5/2014 & 5/6/2015 1/6/20	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratewn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data no wastiable. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warming for use in children and adolescents.  Not under perview of PMAC as they are not adolescents. Must be given with 300-cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC not and FDA regulated medication/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - QT prolongation.  Higher risk of sucided per FDA advisory. Reports of liver failure.  No longer available on the market.  No longer available on the market.  No advantage over trazodone its When used for insommnia.  ADR profile: EKG changes - QT prolongation.  Higher risk of sucided per FDA advisory. Reports of liver failure.  Only for children =15yrs old.  Similar to other methylpheniciate products already approved.  Only for children =15yrs old.
Cyleit Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamical XR Latuda Lopressor Melatonin Mellari Minipres Moban Moban Moban Oleptro Orap Paxil Frolixin decanoate Quillivant Risperdal Consta Rezorem Saphras Serzone Sonata Tenormin	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 6/5/2015 6/5/2015 3/5/2014 & 5/6/2011 3/5/2014 & 5/6/2011 3/5/2014 & 4/6/2015 10/8/2004 & 4/4/2015 10/8/2004 & 5/1/2015 4/1/2005 10/9/2009 & 5/5/2011 4/4/2014 8/6/2011 10/5/2004 8/6/2009 & 5/6/2011 4/6/2009 1/6/05 & 5/6/2014 6/5/2009 & 2/7/13 12/4/2009 1/6/05 & 2/7/13 12/4/2009 1/6/05 & 2/7/13 12/4/2009 1/6/5/2004 & 6/5/2004 1/6/2009 & 3/5/2014 1/6/2011	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratem from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concer No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Also adolescents.  But with a warming for use in children and adolescents.  But with a warming for use in children and adolescents.  Not under pervise of data reparding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under pervise of PMAC. An art PDA regulated medication/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - OT prolongation.  Approved with spe based max dolescent.  Approved with spe based max dolescent.  Not advantage over trazodene iR when used for insommnia.  ADR profile: EKG changes - OT prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.  Only for children =15yrs old.  Similar to other methylpheniciate products aready approved.  Only for children =15yrs old.  Removed due to lack of data regarding use
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Felbatol Haldiol Decanoate Gabitrii Inturii Invega I	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2009 & 5/6/2011 4/4/2014 8/6/2010 9/4/2009 & 5/6/2011 4/6/2014 8/6/2010 1/6/05, 5/5/05, 1/6/05 8/5/2004 6/5/2009 & 2/1/13 12/4/2009 11/5/2010 8/6/2010 9/5/2004 4/5/2013 4/4/2014 4/5/2013 4/4/2014 4/5/2013 4/4/2014 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 8/6/2001 8/6/2001 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 8/6/2001 9/4/2009 1/1/5/2015 8/6/2001 9/4/2009 1/1/2015 8/6/2001	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safely and efficacy in children for psychiatric indications. Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available. Approved as per FDA approval restricted to: GAD, Ages 7-17 Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy. Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concer No. indication for use as a psychotropic medication in children. Lack of safety and efficacy data in children and adolescents. Lack of safety and efficacy data in children and adolescents. Lack of safety and efficacy data in children and adolescents. Lack of safety safety and efficacy that in children and adolescents. Lack of safety-efficacy data in children and soft and efficacy in the same product. Safety and efficacy data in children and adolescents. Lack of safety-efficacy data in children and adolescents. But with a warning for use in children and adolescents. But with a warning for use in children 415yrs old dure to lack of evidence for safety and efficacy in this age group. Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase protactin levels. Removed due to lack of safety data and experience with use in children and adolescents. Not under perview of PMAC; not an FDA regulated medication/possible inconsistency in formulations of the same product. ADR profile: EKG changes - OT prolongation. Approved with gae based max dosing Associated with weight loss vs. gain. To remain on the approved drug list. No advantage over trazodone IR when used for insommnia. ADR profile: EKG changes - OT prolongation. Higher risk of suicide per FDA advisory. Reports of liver failure. Only for children -13yrs old. Similar to other methylphenidate products already approved. Only for children -14yrs old
Cylert Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lopressor Melatonin Mellari Minipres Moban Moban Oleptro Orap Paxil Prolixin decanoate QuilliVant Risperdal Consta Rozorem Saphras Sarzone Sonata Tenormin Topamax	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 1/05/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2014, 4/10/2015 10/8/2004, 5/1/2015 4/1/2005 10/8/2009, 3/5/2010 9/4/2004 4/4/2014 8/6/2011 4/4/2014 8/6/2015 10/8/2009, 3/5/2010 9/4/2009 1/6/05 & 5/6/2011 11/6/2010 9/4/2009 1/6/05 & 2/1/13 12/4/2009 11/6/2015 9/5/2004 4/4/2014 4/5/2013 4/4/2014 4/5/2013 4/4/2014 4/5/2013 4/4/2014 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 9/5/2003 3/5/2010, 5/6/2011, 4/10/2015 4/4/2014 4/5/2013 4/4/2014 4/5/2013 4/4/2014 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 5/1/2015 5/1/2015 5/1/2015 5/1/2015 5/1/2015 9/4/2009 12/1/2006, 5/1/2015	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratem from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concer No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warming for use in children and adolescents.  But with a warming for use in children and adolescents.  Not under pervise of data reparding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under pervise of PMAC. And are PDA regulated medication/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - GT prolongation.  Approved witing eight Loss (with the proposed and proposed drug list.  No advantage over trazodone in the when used for insommnia.  ADR profile: EKG changes - GT prolongation.  Higher risk of suicide per FDA advisory. Reports of liver failure.  Only for children >=1 3yrs old.  Similar to other methylphenicate products aready approved.  Only for children >=1 3yrs old.
Cyleit Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitri Invega Invega Sustena Lamictal XR Latuda Lupressor Melatorini Mellari Minipres Moban	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2009 & 5/6/2011 4/4/2014 8/6/2010 9/4/2009 & 5/6/2011 4/6/2014 8/6/2010 1/6/05, 5/5/05, 1/6/05 8/5/20204 6/5/2009 & 2/1/13 12/4/2009 11/5/2010 8/6/2010 9/5/2004 6/5/2009 & 2/1/13 12/4/2009 3/5/2004, 06/05/2015 4/4/2014 4/5/2013 4/4/2014 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 8/6/2001 5/6/2001, 5/6/2011, 4/10/2015 8/6/2001 5/6/2001, 5/6/2011, 4/10/2015 8/6/2001 5/1/2005, 5/1/2015 12/1/2005 5/1/2005, 5/7/2010	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratamn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and solescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety-efficacy data now available. Reviewed and approved.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children and adolescents.  But with a warning for use in children and adolescents.  Not under perview of PMAC as they are not adolescents.  Not under perview of PMAC and the purpose of adolescents and the purpose of the purp
Cyleit Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Moban M	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 6/5/2015 6/5/2015 3/5/2014 & 5/6/2011 3/5/2014 & 4/6/2015 10/8/2004 & 4/4/2015 10/8/2004 & 5/1/2015 4/1/2005 10/9/2009 & 5/6/2011 4/4/2014 8/6/2010 9/4/2009 & 5/6/2011 4/4/2014 8/6/2010 1/6/05 & 5/6/2011 4/6/2010 1/6/05 & 5/6/2011 1/6/2010 9/6/2009 & 6/6/2009 1/6/05 & 6/6/2009 1/6/2009 & 6/6/2009 1/6/200	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwam from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and adolescents. Need for careful literation is a concern. QTC interval and orthostasis are a concern No indication for use as a psychiatry in children for psychiatric indications.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product. Safety and efficacy data in children. Now has FDA approval for use in children. Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Allow and observed in the safety and efficacy in this age group.  Pending release of data reparting use in children or adolescents.  But with a warning for use in children x15yrs old dure to lack of evidence for safety and efficacy in this age group.  Pending release of data reparting use in children or adolescents.  Not under perview of PMAC and a FDA regulated medication/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - OT protongation.  Approved with sape based max closing  Associated with weight loss vs. gain. To remain on the approved drug list.  Not longer available on the market.  ADP profile: EKG changes - OT protongation.  APP profile: EKG changes - OT protongation.  APP profile: Live troxicity.  Removed due to lack of data regarding use in children and adolescents.  Can be deficacy in children and child
Cyleit Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Falbatol Haidol Deanoate Gabitri Invega Invega Sustena Lamictal XR Latuda Lopressor Melatonin Melari Minpres Moban Moban Moban Moban Moban Moban Moban Siepto Grap Siepto Sie	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 5/7/2010 & 10/5/2012 6/5/2015 3/5/2014 & 5/6/2011 3/5/2010, 4/10/2015 10/8/2009 & 4/4/2014 10/8/2004, 5/1/2015 4/1/2009 & 5/6/2011 4/4/2014 8/6/2010 9/4/2009 8.5/6/2011 4/6/2014 8/6/2010 1/6/05, 5/5/05, 1/6/05 8/5/2004 6/5/2009 & 2/1/13 11/5/2010 8/6/2010 9/5/2004 6/5/2009 & 2/1/13 4/4/2014 4/5/2013 4/4/2014 4/5/2013 4/4/2014 9/4/2009 3/5/2010, 5/6/2011, 4/10/2015 8/5/2001 5/6/2015 1/1/2015 8/5/2001 5/5/2005 5/1/2015	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withdrawn from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful titration is a concern. QTC interval and orthostasis are a concern. No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Lack of safety-efficacy data in owards or in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children for a adolescents.  But with a warning for use in children and adolescents.  Not under perview of PMAC and the proving use in children or adolescents. Must be given with 300cal meal. May increase protactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC and to a FDA regulated medication/possible inconsistency in formulations of the same product.  ADR profile: EKG changes - OT prolongation.  Approved with sepalable on the market.  No advantage over trazodone IR when used for insommnia.  No longer available on the market.  No advantage over trazodone IR when used for insommnia.  No longer available on the market.  No advantage over trazodone IR when used for insommnia.  No longer available on the market.  No advantage over trazodone IR when used for insommnia.  No longer realizable on the market.  No advantage over trazodone IR when used
Cyleit Cymbalta Cymbalta Cymbalta Cymbalta Cymbalta Effexor Fanapt Felbatol Haldol Decanoate Gabitril Herbals/Nutritional Suppl Intuniv Invega Invega Sustena Lamictal XR Latuda Lupressor Melatonin Moban M	1/7/2011 8/5/2004 2/4/05 & 5/5/00 2/4/05 & 5/5/00 2/4/05 & 5/5/001 6/5/2015 6/5/2015 3/5/2014 & 5/6/2011 3/5/2014 & 4/6/2015 10/8/2004 & 4/4/2015 10/8/2004 & 5/1/2015 4/1/2005 10/9/2009 & 5/6/2011 4/4/2014 8/6/2010 9/4/2009 & 5/6/2011 4/4/2014 8/6/2010 1/6/05 & 5/6/2011 4/6/2010 1/6/05 & 5/6/2011 1/6/2010 9/6/2009 & 6/6/2009 1/6/05 & 6/6/2009 1/6/2009 & 6/6/2009 1/6/200	N N N N N N N N N N N N N N N N N N N	Removed due to lack indication for use in children and adolescents.  Withfratwan from market  Lack of data re safety and efficacy in children for psychiatric indications.  Only 1 Lilly sponsored study completed. Additional studies in pipeline. Deny approval until efficacy data is available.  Approved as per FDA approval restricted to: GAD, Ages 7-17  Higher risk of suicide per FDA advisory. New Study shows acceptable safety and efficacy.  Lack of safety-efficacy data in children and or adolescents. Need for careful litration is a concern. QTC interval and orthostasis are a concern No indication for use as a psychotropic medication in children.  Lack of safety and efficacy data in children and adolescents.  Lack of safety and efficacy data in children and adolescents.  Not under perview of PMAC as they are not FDA regulated medications/possible inconsistency in formulations of the same product.  Safety and efficacy data no wardiable. Reviewed and approved.  Lack of safety-efficacy data in children. Now has FDA approval for use in children.  Lack of safety-efficacy data in children and adolescents.  But with a warning for use in children Allows of the same product.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC and a FDA regulated medications/possible inconsistency in this age group.  Pending release of data regarding use in children or adolescents. Must be given with 300cal meal. May increase prolactin levels.  Removed due to lack of safety data and experience with use in children and adolescents.  Not under perview of PMAC and are PDA regulated medications/possible inconsistency in formulations of the same product.  ARR profile: EKG changes - OT prolongation.  Approved with age based max dosing  Associated with weight loss vs. gain. To remain on the approved drug list.  Not longer available on the market.  ADP profile: EKG changes - OT prolongation.  Ripher risk of suicide per FDA achievory. Reports of liver failure.  Only for children >=1 Syr